JP2012516140A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516140A5
JP2012516140A5 JP2011546814A JP2011546814A JP2012516140A5 JP 2012516140 A5 JP2012516140 A5 JP 2012516140A5 JP 2011546814 A JP2011546814 A JP 2011546814A JP 2011546814 A JP2011546814 A JP 2011546814A JP 2012516140 A5 JP2012516140 A5 JP 2012516140A5
Authority
JP
Japan
Prior art keywords
polypeptide
isolated
cell
oligopeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011546814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516140A (ja
JP5792630B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/050839 external-priority patent/WO2010086294A2/en
Publication of JP2012516140A publication Critical patent/JP2012516140A/ja
Publication of JP2012516140A5 publication Critical patent/JP2012516140A5/ja
Application granted granted Critical
Publication of JP5792630B2 publication Critical patent/JP5792630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011546814A 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Active JP5792630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14789209P 2009-01-28 2009-01-28
US61/147,892 2009-01-28
EP09151495 2009-01-28
EP09151495.0 2009-01-28
PCT/EP2010/050839 WO2010086294A2 (en) 2009-01-28 2010-01-26 Pan-dr binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2012516140A JP2012516140A (ja) 2012-07-19
JP2012516140A5 true JP2012516140A5 (enExample) 2013-03-14
JP5792630B2 JP5792630B2 (ja) 2015-10-14

Family

ID=42025833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546814A Active JP5792630B2 (ja) 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用

Country Status (4)

Country Link
US (2) US9249187B2 (enExample)
EP (1) EP2391635B1 (enExample)
JP (1) JP5792630B2 (enExample)
WO (1) WO2010086294A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
EP3331544A4 (en) 2015-08-07 2019-03-27 University Of Virginia Patent Foundation IDENTIFICATION OF CLASS 1 MHC ASSOCIATED GLYCOPEPTIDES AS OBJECTIVES TO CANCER IMMUNOTHERAPY
CN109748952B (zh) * 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
EP3807210A4 (en) * 2018-06-13 2022-05-11 The Scripps Research Institute NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS
US20220383996A1 (en) 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
WO2023161527A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants
WO2025231560A1 (en) * 2024-05-08 2025-11-13 The Governing Council Of The University Of Toronto Vaccine to mobilize b cells for therapy

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
JP3566284B2 (ja) 1991-08-26 2004-09-15 ザ スクリップス リサーチ インスティテュート Ｂ型肝炎ウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド類
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP1704868A1 (en) 1992-08-07 2006-09-27 Pharmexa Inc. HLA binding peptides and their uses
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
EP0687182B1 (en) 1993-02-26 2003-08-06 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
WO1994026774A1 (en) 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
CA2168583C (en) 1993-08-02 2007-10-02 Francis V. Chisari Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
AU702517B2 (en) 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
WO1996040213A1 (en) 1995-06-07 1996-12-19 Cytel Corporation Manufacture and purification of peptides
PT876398E (pt) 1996-01-24 2002-12-31 Epimmune Inc Inducao de respostas imunitarias contra determinantes desejados
EP0914142B9 (en) * 1996-03-11 2012-01-04 Epimmune Inc. Peptides with increased binding affinity for at least three hla-a3-like molecules
BR9708220A (pt) 1996-03-21 2000-01-04 Epimmune Inc Peptìdios de ligação hla-a2.1 e seus usos
WO2004089973A2 (en) 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
AU6140998A (en) 1997-01-31 1998-08-25 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
ES2217585T3 (es) 1997-10-10 2004-11-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
EP1064022A4 (en) 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
CA2685270C (en) 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
CA2332786A1 (en) * 1998-05-29 1999-12-02 Epimmune Inc. Identification of broadly reactive dr restricted epitopes
CA2330824A1 (en) 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
WO2000044775A2 (en) 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
AU5898400A (en) 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
CA2377525A1 (en) 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1225907A4 (en) 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
JP4776131B2 (ja) 1999-11-18 2011-09-21 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関連方法
CA2393339A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
WO2001042270A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
WO2001041787A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
JP2003516131A (ja) 1999-12-10 2003-05-13 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｐ５３に対する細胞性免疫応答の誘導
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1242049A4 (en) * 1999-12-13 2005-01-05 Epimmune Inc VACCINE COMPOSITIONS AND ANTIGEN PEPTIDES ASSOCIATED WITH CLASS I HLA-A2 TUMOR
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP1244465A4 (en) 1999-12-21 2005-01-12 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO ANTIGENS OF PROSTATE CANCER USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
MXPA02006554A (es) 1999-12-28 2003-09-22 Epimmune Inc Minigenes optimizados y peptidos codificados por los mismos.
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2400215A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
JP2004522415A (ja) 2000-09-01 2004-07-29 エピミューン インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
CA2421448A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
AU2000275748A1 (en) 2000-09-01 2002-03-22 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
CN1454082A (zh) 2000-09-08 2003-11-05 艾普免疫公司 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
EP1455816A4 (en) 2000-10-19 2007-03-28 Epimmune Inc HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
AU2003221831A1 (en) 2002-04-05 2003-10-27 Epimmune Inc. Heteroclitic analogs and related methods
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
JP2006501827A (ja) 2002-10-03 2006-01-19 エピミューン インコーポレイテッド 最適化されたマルチエピトープ構築体及びその使用
CA2509197A1 (en) 2002-12-06 2004-06-24 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum antigens and methods of use
EP1583548A4 (en) * 2002-12-10 2007-10-17 Epimmune Inc PEPTIDES DIRECTED AGAINST ANTIGENS ASSOCIATED WITH HLA-A1, A2 -A3, -A24, -B7, AND -B44 TUMORS AND COMPOSITIONS
EP1609107A4 (en) 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
PT1620456E (pt) * 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
AU2005250170A1 (en) 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
US20090317412A1 (en) * 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2007137586A2 (en) * 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
EP2069376A4 (en) 2006-07-21 2013-10-16 Pharmexa Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
US9910646B2 (en) 2015-12-26 2018-03-06 Intel Corporation Technologies for native code invocation using binary analysis

Similar Documents

Publication Publication Date Title
JP2012516140A5 (enExample)
JP6826027B2 (ja) インフルエンザ抗原送達用のベクターおよび構築体
CN102666575B (zh) 分枝杆菌疫苗
Babin et al. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP
JP2013517783A5 (enExample)
JP2014500724A5 (enExample)
JP2014503172A5 (enExample)
JP2010529860A5 (enExample)
JP2015521467A5 (enExample)
JP2012501959A5 (enExample)
JP2009540801A5 (enExample)
JP2011516070A5 (enExample)
JP2015501656A5 (enExample)
JP2019506175A5 (enExample)
JP2006149406A5 (enExample)
JP2015212284A5 (enExample)
JP2015509707A5 (enExample)
JP2012515557A5 (enExample)
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
BR112015013387B1 (pt) Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas
JP2013520487A5 (enExample)
JP2010532656A5 (enExample)
HRP20130022T1 (hr) Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora
JP2014504297A5 (enExample)
JP2020502075A5 (enExample)